April 16, 2019
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3030
Washington, D.C. 20549
Attn: Sonia Bednarowski
Re: Millendo Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 5, 2019
File No. 333-230749
Acceleration Request
Requested Date: April 18, 2019
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-230749), as amended (the Registration Statement), to become effective on April 18, 2019, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the Staff). The Registrant hereby authorizes each of Nicole Brookshire, Miguel J. Vega and Daniel Goldberg of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Nicole Brookshire of Cooley LLP at (617) 937-2357.
[Signature page follows]
|
Very truly yours, | |
|
| |
|
Millendo Therapeutics, Inc. | |
|
| |
|
By: |
/s/ Louis J. Arcudi, III |
|
| |
|
Louis J. Arcudi, III | |
|
Chief Financial Officer |
cc: Nicole Brookshire, Cooley LLP
Miguel J. Vega, Cooley LLP
Daniel Goldberg, Cooley LLP
Darah Protas, Cooley LLP